| Lyke, Kirsten E |
NCT04889209: Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines |
|
|
| Completed | 1/2 | 867 | US | Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1 | National Institute of Allergy and Infectious Diseases (NIAID) | COVID-19 | 06/23 | 06/23 | | |
| Active, not recruiting | 1 | 72 | US | Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID), HTNV vaccine using TDS ID, Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), HTNV vaccine using TDS IM, Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), PUUV vaccine using TDS ID, Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), PUUV vaccine using the TDS IM, Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), HTNV/PUUV vaccines using the TDS ID, Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM), HTNV/PUUV vaccines using the TDS IM | U.S. Army Medical Research and Development Command | Hantaan Virus Disease, Puumala Virus | 12/22 | 04/23 | | |
NCT05604521: A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI |
|
|
| Terminated | 1 | 31 | US | PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline, Placebo | Sanaria Inc., University of Maryland, Baltimore, National Institute of Allergy and Infectious Diseases (NIAID) | Malaria, Malaria,Falciparum | 09/23 | 09/23 | | |
| Completed | 1 | 29 | US | Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose, Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Medium Dose, Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - High Dose | University of Maryland, Baltimore, Medical Technology Enterprise Consortium (MTEC) | Dengue | 01/24 | 01/24 | | |
| Clinic, VRC |
NCT05627258: A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults |
|
|
| Completed | 1 | 23 | US | VRC-HIVMAB0115-00-AB | National Institute of Allergy and Infectious Diseases (NIAID) | HIV | 07/24 | 07/24 | | |
NCT04896086: First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults |
|
|
| Completed | 1 | 35 | US | VRC-GENADJ0110-AP-NV, Flucelvax, VRC-FLUMOS0111-00-VP (FluMos-v1) | National Institute of Allergy and Infectious Diseases (NIAID) | Influenza, Seasonal Influenza | 01/24 | 02/24 | | |
NCT03878121: Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers |
|
|
| Recruiting | 1 | 300 | US | Ad4-Env145NFL, Ad4-Env150KN, VRC-HIVRGP096-00-VP (Trimer 4571) with alum | National Institute of Allergy and Infectious Diseases (NIAID) | Healthy Volunteer | 04/25 | 04/25 | | |
NCT05398796: Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults |
|
|
| Completed | 1 | 40 | US | mRNA -1215 | National Institute of Allergy and Infectious Diseases (NIAID), Moderna TX, Inc | Nipah Virus Infection | 09/24 | 09/24 | | |
NCT06585891: Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults |
|
|
| Recruiting | 1 | 60 | US | VRC-HIVMAB0121-00-AB | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infection | 06/26 | 06/27 | | |
NCT05968989: Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults |
|
|
| Recruiting | 1 | 40 | US | VRC-FLUMOS0116-00-VP( FLUMos-v2) | National Institute of Allergy and Infectious Diseases (NIAID) | Influenza | 12/25 | 12/25 | | |
NCT01132859: VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older |
|
|
| Recruiting | N/A | 500 | US | | National Institute of Allergy and Infectious Diseases (NIAID) | Immunity, Mucosal, Immune System Processes, Blood Specimen Collection | | | | |
NCT00067054: Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies |
|
|
| Recruiting | N/A | 3000 | US | | National Institute of Allergy and Infectious Diseases (NIAID) | Sample Collection | | | | |
| Recruiting | N/A | 4000 | US | | National Institute of Allergy and Infectious Diseases (NIAID) | Screening | | | | |
| Holman, Lasonji A |
| Recruiting | N/A | 4000 | US | | National Institute of Allergy and Infectious Diseases (NIAID) | Screening | | | | |
